Article | £200m+ invested in Babraham Campus companies, what lies ahead? (Clone)
July 14, 2021 | Featured on Business Weekly
Derek Jones, Chief Executive of the Babraham Research Campus
CAMBRIDGE, Wednesday 14 July 2021 —On Wednesday 14 July 2021, bit.bio attended The Babraham Investor Conference 2021 (BIC), an event for investors focusing on early-stage and scale-up life science and med-tech companies. bit.bio Co-Founder Florian Schuster was the second scale-up speaker.
Derek Jones, Chief Executive of the Babraham Research Campus opened the event by outlining how the Campus directly impacts the investor community: “Research has shown that investors see a 7.2 x return on investments on average in Campus companies.”
Florian revealed how bit.bio is coding human cells for health, to precision engineer the next generation of medicine.
Florian Schuster Co-Founder, CFO and COO bit.bio said:
“We are solving the manufacturing problem of human cells which allows us to overcome the major problems our sector is currently facing: the reproducibility issues in scientific research, the translational gap in drug development, and to make cell therapies consistent and scalable.”
bit.bio has raised more than £50 million in seed and Series A funding.